Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Top Cited Papers
- 1 May 2016
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (5) , 651-662
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (NIH) (grant (number T32 CA 009621))
- NIH ((5R01CA168863))
This publication has 30 references indexed in Scilit:
- A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinomaBMC Cancer, 2012
- Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to ResistanceCancer Cell, 2012
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisNature, 2011
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to ChemotherapyCancer Discovery, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Regulation of immune responses by L-arginine metabolismNature Reviews Immunology, 2005